Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ML 007/muscarinic antagonist - MapLight Therapeutics

Next Previous
Drug Profile

ML 007/muscarinic antagonist - MapLight Therapeutics

Alternative Names: ML-007/muscarinic antagonist combination tablet - MapLight Therapeutics; ML-007/PAC; ML-007C-MA

Latest Information Update: 07 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MapLight Therapeutics
  • Class Antipsychotics
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psychotic disorders; Schizophrenia

Most Recent Events

  • 05 Jan 2026 ML 007/muscarinic antagonist - MapLight Therapeutics receives Fast Track designation for Psychotic disorders [PO,Controlled release] in USA
  • 15 Aug 2025 Phase-II clinical trials in Psychotic disorders in USA, Canada (PO) (NCT06887192)
  • 07 Jul 2025 MapLight Therapeutics plans a phase II trial for Alzheimer's disease Psychosis (PO), in 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top